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Abstract
Introduction: The role of CD4+ T cells in the immunopathogenesis of asthma is well documented. Little is known about the
role of CD8+ T cells. The aim of this study was to assess peripheral blood subsets of CD4+ and CD8+ T cells expressing
naive/memory markers (CD45RA+/RO+) and the activation marker (CD25+) in children with allergic asthma.
Materials and Methods: Peripheral blood mononuclear cells were isolated from children with allergic asthma and healthy chil-
dren. T cell subsets were analyzed by flow cytometry for the expressions of CD45RA, CD45RO, and CD25. In this study,
some differences in the memory compartment of peripheral blood T cells between asthmatic children and healthy controls
were detected.
Results: The absolute number of CD8+ T cells expressing CD45RO was significantly elevated and the percentages of CD3+
T cells expressing activation marker CD25 and of CD4+ T cells expressing memory marker CD45RO were significantly lower
in children with asthma compared with controls. No correlation was found between severity of asthma and peripheral blood
lymphocyte subsets.
Conclusions: There were some differences in the memory compartment of peripheral blood T cells between asthmatic chil-
dren and healthy controls. The increase in the number of CD8+ T cells expressing the memory marker (CD45RO) in chil-
dren with allergic asthma may indicate that CD8+ T cells play a role in the pathogenesis of asthma.
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INTRODUCTION
Allergic asthma is one of the most common diseases in
childhood that result from both genetic and environmen-
tal factors. Numerous studies have underlined the role of
activated memory CD4+ T cells as the main producer of
Th2 cytokines in asthma and other atopic diseases. Th2
cytokines such as IL-4 and IL-13 interact with resident
lung cells, including airway epithelium, myofibroblast, and
smooth muscle cells, to induce the asthmatic phenotype
[14]. These cytokines contribute to many of the patho-
physiological features of asthma, including airway inflam-
mation, mucus secretion, and airway hyperresponsiveness.
The production of Th2 cytokines was initially ascribed to
CD4+ T cells, but several studies have provided evidence
that CD8+ T cells are able to secrete Th2 cytokines and
are also essential for allergic inflammation and airway sen-
sitivity [14]. The importance of CD8+ T cells in the patho-
genesis and exacerbation of allergic disease has been
recently highlighted by the identification of allergen-spe-
cific CD8+ T cells [21]. It is assumed that an increase in
activated memory T cells (CD54RO/CD25) in the lung or
in peripheral blood may be evidence of chronic inflamma-
tion in an asthmatic subject.
This study was performed to compare the expres-
sions of the naive memory marker (CD45RA+/
/CD45RO+) and the activation marker (CD25+) on
peripheral blood T cells between asthmatic children and
healthy controls. Inhaled glucocorticosteroids (IGCs)
are the first-line anti-inflammatory treatment of asthma
and such treatment is associated with reduced peripher-
al blood T cell activation. Therefore we hypothesized
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by long-term IGCs therapy. Less is known about the
effects of long-term IGCs therapy on humoral immunity
in asthmatic children. To check if there are some differ-
ences in basal parameters assessing humoral immunity we
evaluated serum IgA, IgM, and IgG levels in both groups.
MATERIALS AND METHODS
The study group consisted of 47 children (aged 3–18
years) with allergic asthma. Ten had intermittent, 21 mild,
12 moderate, and 4 severe persistent asthma. All the chil-
dren had attended the outpatient clinic at the
Department of Pediatric Gastroenterology, Allergology
and Developmental Disorders, Medical University of
Silesia, Zabrze, for at least one year before recruitment
into the study and had positive skin prick tests (SPTs) for
one or more allergens (a SPT was regarded as positive
when the mean diameter was at least 3 mm in the pres-
ence of negative diluent and positive histamine controls).
All the children had significantly elevated total and rele-
vant allergen-specific IgE levels. The diagnosis of asthma
and the assessment of severity were done according to the
GINA 2002 protocol [19]. All the children had a history of
recurrent episodes of airway obstruction. Children under
six years of age underwent spirometric assessment and
presented airway obstruction reversibility, as documented
by positive bronchodilator responses of 12% FEV1
increase. Eight children younger than five years of age
had parental histories of asthma and/or personal histories
of atopic dermatitis (AD) and at least four episodes of
wheezing and hospitalization for asthma in the year
before enrollment in this study. Thirty-six children with
mild to severe asthma were treated with regularly inhaled
IGCs, but with a variable daily dose according to the asth-
ma symptoms (at the time of evaluation the daily IGCs
dose ranged from 100 to 1000 µg/day, mean daily dose:
264.5±41.94). The duration of IGCs treatment ranged
from 2 months  to 10 years. Fifteen asthmatic children had
a history of AD and 23 had concomitant rhinitis symp-
toms. Detailed data of asthma duration and IGCs treat-
ment were obtained from medical records and an inter-
view questionnaire. The control group consisted of 50
healthy children (aged 3–17.5 years) with a negative his-
tory of allergic disease, normal levels of total serum IgE,
and negative results of SPTs to a panel of inhaled aller-
gens (dust mite, mixed grass or tree pollen, cat, dog;
Allergopharma, Reinbek, Germany). The control chil-
dren attended the outpatient pediatric clinic for non-
-immunological, non-inflammatory problems and required
venous blood collection for routine laboratory tests.
The present study was approved by the Ethics
Committee of the Medical University of Silesia in
Katowice and written informed consent was obtained
from the children’s parents.
Venous blood samples were obtained from each sub-
ject. The serum concentrations of total and specific IgE
were measured using commercially available enzyme-
-linked immunosorbent assay kits (IU/ml, Allergo-
pharma; detection threshold 1.0 IU/ml). Levels of total
IgG, IgM, and IgA were determined by turbidimetry
(COBA-S INTEGRA – 800).
Lymphocyte subsets in peripheral blood
Lymphocyte populations were analyzed by multipara-
meter flow cytometry with 3-color analyses. Phenotypes of
the T cell populations were obtained with PerCP anti-CD3
antibody plus combinations of FITC- and PE-labeled anti-
bodies specific to CD4, CD8, CD25, CD45RA, and
CD45RO. The cells were stained with the appropriate iso-
tope control antibodies and nonspecific staining was not
observed. The antibodies used for flow cytometry were
purchased from Becton Dickinson (San Jose, CA, USA).
After staining, analysis was performed on a FACScan
(Becton Dickinson) equipped with an argon laser tuned to
488 nm. The data were acquired and analyzed with Cell
Quest software (Becton Dickinson). The proportion of
lymphocytes stained with each monoclonal antibody was
converted to the absolute count per microliter by multiply-
ing the absolute number of lymphocytes per microliter
derived from the complete blood count.
Statistical analysis was performed using the Statistica
version 3.0 software package and data are presented as
the mean value ±SE. The Mann-Whitney U-test was
used for comparisons between groups. Correlations were
calculated using Spearman’s rank correlation test. Values
of p<0.05 were considered statistically significant.
RESULTS
The demographic and background characteristics of
the children studied are shown in Table 1. These two
groups were similar with regard to age.
Comparison of eosinophil counts and serum IgA, IgM, IgG,
and IgE levels between the children with asthma and controls 
The percentage as well as the absolute count of
peripheral blood eosinophils was significantly elevated in
the asthmatic children compared with the control group
(p<0.0005 and p<0.00005, respectively). Total serum
IgE levels were significantly higher in the children with
asthma (p<0.0005). Although serum IgA, IgM, and IgG
levels in the children with asthma were within the normal
range, IgM and IgG levels were significantly lower than
in the controls (p<0.05 and p<0.01, respectively).
Expression of the naive/memory (CD45RA+/CD45RO+)
markers on lymphocyte subsets in the children 
with asthma and the control group
The mean percentages, counts, and SE for all the
lymphocyte populations are shown in Table 2. Flow-
-cytometric analysis revealed no statistically significant
differences in the percentages of CD3+, CD4+, CD8+
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Table 1. Demographic and clinical characteristics of patients with asthma
Asthma patients Controls
Number 47 50
Age (years, mean ±SE) 9.4±3.9 8.4±1.1
Sex (M/F) 32/15 26/24
Mean duration of asthma (years, mean ±SE) 5.8±0.63
Concomitant disorders:
rhinitis 23 (47.9%)
history of AD 15 (31.25%)
serum total IgE level 347±36.031 IU/ml 28.1±2.4 IU/mla
eosinophil % (number) 6.9±0.95 (260±12.5) 2.3±0.5b (137±11)c
IgA 1.37±0.09 g/l 1.53±0.11
IgM 1.1±2.1 g/l 1.54±0.12d
IgG 9.09±0.35 g/l 10.57±0.44e
LDH 655±35.6 U/l 760±40 U/l
cortisol 15±0.85 µg/dl 16.29±1.46 µg/dl
positive SPT 47 (100%) 0
Dermatophagoides pteronyssimus
D. farinae 39 (82.9%)
grass pollens 40 (85.1%)
tree pollens 22 (46.8%)
weed pollens 11 (23.4%)
moulds 15 (31.9%)
feather 12 (25.53%)
cat 5 (10.6%)
dog 10 (21.29%)
FEV1% predicted 3 (6.38%)
FEV1/FVC 85.0±2.8 89.9±2.5f
87.7±2.0 93.3±3.0g
ap<0.0005, bp<0.0005, cp<0.00005, dp<0.05, ep<0.01, fp<0.05, gp<0.005
Table 2. Mean percentages and numbers of lymphocyte subsets in the peripheral blood of asthma children and healthy controls
T cell phenotype Asthma (%, number mean ±SE) Healthy (%, number mean ±SE)
CD3+ 64±1.1 67±0.96
1991±126 1741±75
CD4+ 37±1.0 39±1.07
1155±77.7 1035±52
CD8+ 26±1.0 27.6±0.92
789±49.5 736±35.2
CD3+CD25+ 5.8±0.8a 7.9±0.76
193.2±39.2 218.2±28.6
CD4+CD25+ 3.81±0.1 4.8±0.56
116.4±8.6 118±16.3
D45RA+ 73±1.3 72±1.0
2336.5±170.2 1760±140.0
CD4+CD45RA+ 24.6.±1.2 27.34±1.1
766.7±74.4 737.7±47.4
CD8+CD45RA+ 22.2±0.8 21.5±0.67
674±46 574±29.5
CD45RO+ 33.4±1.2 34±1.3
989.3±63.4 833.4±66
CD4+CD45RO+ 17.7±0.7b 20.5±0.5
523.8±33.3 540±23.8
CD8+CD45RO+ 9.5±0.62 7.8±0.36
278±22.5c 206.9±23.8
CD4/CD8 1.6±0.1 1.5±0.84
a Percentage of CD3+CD25+ p<0.05; b percentage of CD4+CD45RO+ p<0.0002; c number of CD8+CD45RO+ p<0.025.
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CD45RO+, and CD8+CD45RO+ between the asthma
group and healthy controls. The percentage of
CD4+CD45RO+ was significantly lower in the asthmat-
ic children (p<0.0002), but the absolute count did not
differ between the groups. The CD8+CD45RO+ T cell
count was significantly higher in the asthma group
(p<0.025) than in the healthy children (Fig. 1).
The expression of naïve/memory markers in children
with intermittent asthma (never IGCs treated) and with
persistent asthma (IGCs treated) was similar. No signif-
icant correlation between dose of IGCs and expression
of CD45RA/RO on T cells was found.
Comparison of CD25 expression on CD3+ and CD4+
T cells between the children with asthma
and the control group
The percentage, but not the absolute count, of
CD3+CD25+ was significantly lower in the children with
asthma than in the healthy children (p<0.05). Ex-
pression of CD25 on CD4+ T cells did not differ between
the asthma and control group (Fig. 2). Duration of IGCs
treatment inversely correlated with absolute count of cir-
culating CD3+ and CD4+ T cells expressing the activa-
tion marker CD25 (R: –0.39, p=0.02 and R: –0.38,
p=0.02, respectively). On the other hand, no correlation
was found between the expression of CD25 on peripher-
al blood CD3+ and CD4+ T cells and duration of asthma.
Correlation between severity of asthma 
and immune parameters
Severity of asthma positively correlated with dura-
tion of asthma as well as serum IgE levels (R: 0.66,
p=0.00001 and R: 0.57, p=0.00002), but inversely with
spirometric parameters such as FEV1 and FEV1/FVC
(R: –0.68, p=0.000002 and R: –0.53, p=0.0004, respec-
tively, Fig. 3). No correlation was found between the
severity of asthma and the age of the children. None of
the examined peripheral blood T lymphocyte subsets
correlated with the severity of asthma.
DISCUSSION
Several studies have demonstrated increased num-
bers of CD4+ and CD8+ in bronchial biopsy specimens
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Fig. 1. Percentages and absolute numbers of the CD4+ and CD8+ peripheral blood T-memory marker CD45RO in the study groups. The
percentage of CD4+CD45RO+ T cells in children with asthma was significantly lower than in healthy children (p<0.0002), but the absolute
numbers did not differ. The percentage of CD8+CD45RO+ T cells tended to be higher (p=0.1) and the number was significantly elevated
in children with asthma compared with healthy children (p<0.025). The Mann-Whitney U-test was used to determine significant differences
between the two groups.
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Fig. 2. Percentages and absolute numbers of CD3+ and CD4+ peripheral blood T cells expressing the activation marker CD25+ in the exam-
ined groups. The percentage of CD3+CD25+ T cells, but not the number, was significantly lower in children with asthma than in controls
(p<0.05). Both the percentages and the numbers of CD4+CD25+ T cells were similar in the groups. The Mann-Whitney U-test was used to
determine significant differences between the two groups.
and bronchoalveolar larvage (BAL) fluid in subjects
with asthma [2, 3]. Also, an imbalance of T cell subsets
was documented in peripheral blood of asthmatics,
especially after allergen challenge or during exacerba-
tion of the disease [11, 15, 22]. In the present study we
could not find differences in the percentages and num-
bers of CD3+, CD4+, and CD8+ T cells between chil-
dren with asthma and non-atopic controls, which is in
line with other reports [9]. However, our findings con-
trast with a recent study by Antunez et al. [1] showing
a decrease in circulating CD8+ T cells in children with
intermittent asthma.
Analyses of bronchial biopsy specimens and cells in
BAL fluid from patients with asthma revealed elevated
levels of activation marker CD25 (IL-2R) expression,
even in the absence of an increase in T cells [2, 6, 13].
Peripheral blood CD4+, CD8+, and memory
(CD45RO) T cells in atopic asthmatics also had higher
expressions of IL-2R molecule compared with healthy
controls [6, 13]. Surprisingly, children with asthma had
a slightly lower number and significantly decreased pro-
portion of CD3+CD25+ T cells and similar proportion
and number of CD4+CD25+ T cells compared with
healthy subjects. A possible explanation for this discrep-
ancy is that most of the children in our study were regu-
larly treated with IGCs, which inhibit T cell activation
[10]. Indeed, there are many studies showing a reduc-
tion in the expression of the activation marker CD25 on
T cells in airways as well as in peripheral blood in asth-
matic patients after steroid treatment [6, 9, 17]. Of inter-
est is that in our study a moderate negative correlation
between the duration of IGCs treatment and the num-
ber of CD3+ and CD4+ T cells expressing the activation
marker CD25 was observed.
It is known that among CD4+ T cells expressing
CD25, a distinct subset with regulatory activity
(CD4+CD25+ Treg) is present. Some recent reports have
suggested the existence of defects in the number or
function of CD4+CD25+ Treg  in atopic individuals.
Unfortunately, in this study we were not able to distin-
guish whether CD4+CD25+ are activated or regulatory
T cells.
Imbalances in memory CD45RO+ T cells in the
peripheral blood of patients with asthma and allergic
disease have been reported, but results are inconsistent
[1, 7, 12, 18]. We showed that the alteration in the
peripheral blood memory T cell subpopulations in
patients with asthma affects both the CD4+ and CD8+
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CD4+CD45RO+ cells was significantly lower in asthma
patients than in controls; however, the absolute counts
did not differ between the groups. The decrease in the
percentage of CD4+CD4+ T cells may indicate that they
were recruited from the peripheral blood to the site of
inflammation, but taking into account the down-regula-
tory effect of glucocorticosteroids (GS) on CD45RO
expression, our findings may also reflect the effect of
long-term IGCs treatment. In previous studies,
decreased expression of CD45RO in lungs [16] as well
as on peripheral blood T cells in patients with asthma
was associated with oral GC [6] or IGCs therapy [9]. On
the other hand, in adult patients with asthma, despite of
using a high dose of IGCs, the expression of CD45RO
on CD4+ T cells was higher in severe asthma than in
milder asthma and healthy controls [12]. In our study no
correlation between severity of asthma and expression
of the memory marker (CD45RO) on CD4+ T cells was
found, although the percentage of CD4+CD45RO+
T cells correlated with the duration of asthma and the
age of the examined patients. A lack of comparison of
the expression of naïve/memory marker on circulating
T cells before and after IGCs treatment in asthmatic
children may be a drawback of this study. It is of note
that the expressions of these markers in asthmatic chil-
dren treated and never treated with IGCs were similar;
moreover, no correlation between the dose of IGCs and
the percentage/absolute count of CD45RO+ T cells was
found. 
In this study of children with asthma, the percentage
of CD8+CD45RO+ T cells tended to be higher and the
number of these cells was significantly elevated com-
pared with non-atopic subjects. This result may suggest
that besides CD4+, CD8+ memory T cells may also be
implicated in the immunopathogenesis of asthma.
Indeed, CD8+ T cells, which are capable of secreting
Th2 cytokines, including IL-4, IL-5, and IL-13, have
been described in asthmatic subjects and in animal
models of asthma. It was shown that the number of
CD8+ T cells in bronchial biopsies in asthma is associat-
ed with a decline in lung function [24]. Also, an
increased cytokine production of sputum CD8+ T cells
has been shown in patients with asthma that was related
to disease severity [5]. Moreover, significantly greater
expression of the activation marker CD25 by CD8+
T cells in peribronchial tissue in fatal asthma has been
observed [20]. 
Some studies suggest that CD8+ T cells are relative-
ly corticosteroid resistant [23]. It was shown that GS
downregulate CD45RO only on CD4+, but not on
CD8+ peripheral blood T cells [6, 9]. This may partially
explain why a decrease in CD8+CD45RO+ T cells was
not observed in our children. 
In this study, similarly to other reports, we also
showed that the severity of asthma correlated with total
serum IgE levels and FEV1, but not with allergen-spe-
cific IgE and eosinophil levels [4]. Surprisingly, we
found significantly decreased serum IgM and IgG con-
centrations in asthmatic children in comparison with
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Fig. 3. Correlation between the severity of asthma and total serum IgE levels
(R: 0.57 p=0.00002), FEV1 (R: –0.68, p=0.000002), and duration of asthma
(R: 0.66, p=0.00001).
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ma had serum IgA, IgM, and IgG within the normal
range. We consider the possibility that long-term treat-
ment with IGCs may be associated with this finding,
since a recent study revealed an inhibitory effect of long-
term low-dose GS therapy on humoral immunity [8].
In conclusion, significant differences can be detected
in the memory compartment of CD4+ and CD8+ T cells
in the peripheral blood of children with allergic asthma
compared with healthy age-matched controls. This phe-
nomenon is independent of the severity of the disease.
Some differences in the expressions of activation mark-
ers on peripheral blood T cells may be related to long-
-term use of IGCs by children with asthma. The increase
in CD8+CD45RO+ T cells in children with asthma may
suggest an important role of this lymphocyte subpopula-
tion in the pathogenesis of allergic diseases.
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